Early TAVR And EVOQUE Launches Will Expand Access

Key Takeaways

• Strategic product launches, like the TAVR approval and EVOQUE, position Edwards for significant revenue growth and expanded market share.
  
• Investments in surgical innovation and operational efficiency mitigate financial threats, enhance global therapy adoption, and stabilize earnings.
  
• Tariffs, competitive pressures, and strategic investments could impact Edwards Lifesciences' margins and revenue growth, requiring careful financial planning to achieve targets.

Catalysts

Provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.

• The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future.
  
• The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.
  
• The recent approval of the Sapien M3 in Europe as the world's first transcatheter mitral valve replacement system signals Edwards' ability to address large, unmet patient needs, which could result in substantial revenue growth.
  
• Edwards' ongoing investments in surgical innovation, such as the RESILIA tissue technology, are likely to expand access and adoption of its cardiovascular therapies globally, potentially improving net margins and bolstering revenue.
  
• The company's plan to mitigate the financial impacts of announced tariffs and the JenaValve acquisition while maintaining its EPS guidance of $2.40 to $2.50 demonstrates an operational efficiency that could positively impact earnings.

Edwards Lifesciences Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Edwards Lifesciences's revenue will grow by 9.7% annually over the next 3 years.
• Analysts assume that profit margins will shrink from 26.1% today to 24.4% in 3 years time.
• Analysts expect earnings to reach $1.8 billion (and earnings per share of $3.05) by about May 2028, up from $1.4 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $1.5 billion.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 29.9x on those 2028 earnings, down from 30.5x today. This future PE is lower than the current PE for the US Medical Equipment industry at 30.3x.
• Analysts expect the number of shares outstanding to decline by 2.61% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.95%, as per the Simply Wall St company report.

Edwards Lifesciences Future Earnings Per Share Growth

Risks

• Edwards Lifesciences faces potential financial risks due to the impact of tariffs, which could affect the company's gross margins and net earnings, as they anticipate a $0.05 EPS impact from current tariffs in 2025, with greater impacts expected in 2026.
  
• The acquisition of JenaValve may lead to an EPS dilution of $0.05 to $0.10, which could strain operating margins and necessitate careful planning to offset the acquisition costs in order to maintain earnings per share targets.
  
• The competitive pressure in international markets, such as Japan, is exerting downward pressure on TAVR procedure growth, potentially impacting revenue growth and expansion efforts in these regions.
  
• While Edwards anticipates expanding TAVR indications to asymptomatic patients, the regulatory and policy changes required for this may take longer than expected, delaying the projected revenues from this expanded patient base.
  
• High levels of discretionary R&D spending, as well as necessary strategic investments to offset EPS impacts, indicate that operating expenses could rise, potentially impacting net profit margins if the expected growth in revenues does not materialize accordingly.

Valuation

• The analysts have a consensus price target of $80.299 for Edwards Lifesciences based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $90.0, and the most bearish reporting a price target of just $61.0.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $7.3 billion, earnings will come to $1.8 billion, and it would be trading on a PE ratio of 29.9x, assuming you use a discount rate of 7.0%.
• Given the current share price of $74.92, the analyst price target of $80.3 is 6.7% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.